INFLIXIMAB MODULATES MUCOSAL CYTOKINE PROFILE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES

被引：0
|
作者：
Caprioli, F. [1 ]
Bose, F. [2 ]
Raeli, L. [2 ]
Vigano, C. [3 ]
Basilisco, G. [1 ]
Conte, D. [3 ]
Abrignani, S. [2 ]
Reali, E. [2 ]
机构：
[1] Fdn IRCCS Osped Maggiore Policlin Mangiagalli & R, Gastroenterol Unit 2, Milan, Italy
[2] INGM, Milan, Italy
[3] Univ Milan, Dept Med Sci, Milan, Italy
来源：
DIGESTIVE AND LIVER DISEASE | 2010年 / 42卷
关键词：
D O I：
10.1016/S1590-8658(10)60175-2
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P.62
引用
收藏
页码：S125 / S125
页数：1
相关论文
共 50 条
  • [31] Cytokine profile in children with inflammatory bowel disease
    A. P. Toptygina
    E. L. Semikina
    G. V. Bobyleva
    L. V. Miroshkina
    S. V. Petrichuk
    Biochemistry (Moscow), 2014, 79 : 1371 - 1375
  • [32] Infliximab and amyloidosis secondary to inflammatory bowel diseases - Reply
    Casellas, F
    MEDICINA CLINICA, 2005, 124 (19): : 758 - 758
  • [33] Predictive Factors of Response to Infliximab in Inflammatory Bowel Diseases
    Bourrier, Anne
    Seksik, Philippe
    Sokol, Harry
    Johanet, Catherine
    Nion-Larmurier, Isabelle
    Beaugerie, Laurent
    Cosnes, Jacques
    GASTROENTEROLOGY, 2010, 138 (05) : S688 - S688
  • [34] Pharmacokinetics of Infliximab and Reduction of Treatment for Inflammatory Bowel Diseases
    Nicolas Williet
    Stephane Paul
    Laurent Peyrin-Biroulet
    Xavier Roblin
    Digestive Diseases and Sciences, 2016, 61 : 990 - 995
  • [35] Pharmacokinetics of Infliximab and Reduction of Treatment for Inflammatory Bowel Diseases
    Williet, Nicolas
    Paul, Stephane
    Peyrin-Biroulet, Laurent
    Roblin, Xavier
    DIGESTIVE DISEASES AND SCIENCES, 2016, 61 (04) : 990 - 995
  • [36] Cytokine Profile in Children with Inflammatory Bowel Disease
    Toptygina, A. P.
    Semikina, E. L.
    Bobyleva, G. V.
    Miroshkina, L. V.
    Petrichuk, S. V.
    BIOCHEMISTRY-MOSCOW, 2014, 79 (12) : 1371 - 1375
  • [37] Abnormalities of cytokine regulation in the inflammatory bowel diseases
    Strober, W
    Mannon, PJ
    Fuss, IJ
    GUT-LIVER INTERACTIONS: BASIC AND CLINICAL CONCEPTS, 2006, 146 : 15 - 24
  • [38] Infliximab-Associated Suppression of Cytokine Release by Mucosal Explants Predicts Success of Anti-TNF Therapy in Patients with Inflammatory Bowel Disease
    Otsubo, Takeshi
    Alsahwi, Nassib
    Wahed, Renaisa
    Anand, Rajsavi
    Cheifetz, Adam S.
    Wolf, Jacqueline L.
    Bousvaros, Athos
    Snapper, Scott
    Lamont, J. Thomas
    Robson, Simon
    Moss, Alan C.
    Kokkotou, Efi
    INFLAMMATORY BOWEL DISEASES, 2016, 22 : S43 - S44
  • [39] The Impact of Infliximab Therapy On Colonic Mucosal Expression of Barrier Genes in Patients with Inflammatory Bowel Disease
    Arijs, Ingrid
    Quintens, Roel
    Van Lommel, Leentje
    Van Steen, Kristel
    De Hertogh, Gert
    Van Assche, Gert A.
    Vermeire, Severine
    Geboes, Karel
    Schuit, Frans C.
    Rutgeerts, Paul J.
    GASTROENTEROLOGY, 2009, 136 (05) : A210 - A210
  • [40] Gut mucosal microbiota composition in Inflammatory Bowel Disease introduced to infliximab
    Ventin-Holmberg, R.
    Lindholm, J.
    Eberl, A.
    Taina, S.
    Saavalainen, P.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 1036 - 1036
12345